Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Research & Development history
Currency unavailable · from the income statement
No Research & Development data reported for this period type.
Research & Development vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $171.97M USD | +136.8% | +73.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M USD | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M USD | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $101.99M USD | +14.6% | +8.4% | 46.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M USD | +11.3% | +45.0% | — |
| LTM Mar 2026 | $43.27M USD | +26.5% | +23.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M USD | — | +131.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +20.6% | +45.0% | 293.2% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.